Based on the premise that, in analogy to other targeted cancer therapies, resistance to HSP90 inhibitors will inevitably occur, we sought to prospectively identify underlying mechanisms, which may guide sequential or simultaneous treatment strategies to overcome or prevent escape from HSP90 inhibition. The gene discussed is HSP90AB1; the disease is cancer.